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Dear Sirs,
Thank you for your interest in our manuscript. With plea-
sure, we took time to read your comments. In general, we
would like to state that it is obvious that high level of
evidence research costs time for design of a study, time for
the study to be executed and results to be analysed and
subsequently for the results to be published. In this time
period, the evidence- and eminence-based opinion based on
latest literature can change. This, however, does not
implicate that results from randomised clinical trials with
negative outcome should not be shared with the research
community.
Allow us to comment that you quote the study per-
formed by Farkas et al. [3]. This study is methodologically
very solid. However, it remains an in vitro study with
partly monolayer cultures tested, and partly with osteo-
chondral samples, where both had long times of exposure
to the agents, and in the osteochondral sample group, only
the superficial layer was affected. There are also in vivo
studies to quote when commenting that intra-articular use
of Bupivacaine seems not safe.
The DUPRA trial was primarily designed to come up
with level 1 evidence regarding the effectiveness of single
dose intra-articular Ropivacaine and Bupivacaine after
arthroscopy. During the design of the DUPRA trial, the first
in vivo studies on the safety aspects of intra-articular
injection of Bupivacaine were not yet published, and
therefore the DUPRA trial was without concern regarding
safety approved by the medical ethical committee of the
University of Utrecht. During inclusion, publications on the
safety of intra-articular Bupivacaine and Ropivacaine came
out; the first being an in vitro study by Chu et al. [2]. Other
in vitro studies followed and raised general concern. The
first well-designed in vivo studies were published in 2010
[1]. At this time, inclusion of our study was completed and
data analysis was started. Study results were then presented
at congress meetings as well as a manuscript was written
and prepared for publication in the KSSTA journal.
Although the aforementioned information gives a clear
picture on how it works in the field of research and pub-
lication, we felt that the information from the DUPRA trial
was still very much worth sharing with other researchers in
the field considering that our outcomes provide an extra
definitive argument to stop with the daily use of intra-
articular injection of Bupivacaine or Ropivacaine after
arthroscopy.
Allow us to explain. In daily practice, the discussion on
safety aspects remained viable for the use of single-shot,
low doses of an intra-articular injection with Bupivacaine
or Ropivacaine, simply because of the fact that numerous
colleagues were not convinced of the chondrotoxic effect
of low-dose single-shot intra-articular injections—Bupiv-
acaine and Ropivacaine have time- and dose-dependent
chondrotoxicity [3–5]—and were convinced advocates of
the beneficial effect on pain reduction of these aforemen-
tioned low doses.
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The DUPRA trial failed to demonstrate clinically rele-
vant beneficial effects of both Bupivacaine and Ropivacaine
and therefore ends the discussion. Hence, there is no need to
argue on the details of the safety aspects of low-dose single-
shot intra-articular injections at all anymore, since there is
no clinically relevant beneficial aspect to be expected.
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